Literature DB >> 14723008

Comparing treatment outcomes using utility assessment for health-related quality of life.

Michael W Kattan1.   

Abstract

When comparing treatments, the simple question of which treatment produces a better outcome prompts a complicated answer if both quantity and quality of life are considered. This is particularly evident when the treatment associated with better survival worsens quality of life, at least for part of the time, or when certain aspects of quality of life are better with one treatment while other aspects are better with another treatment. Utility assessment is an evolving discipline that offers an attractive conceptual solution to these problems. The popular approaches are described, and one particular method, the standard gamble, is advocated. Utility is easily measured by the standard gamble, and it has good psychometric and theoretical properties.

Mesh:

Year:  2003        PMID: 14723008

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  5 in total

1.  Quality of life and healthcare use in a randomized controlled lung cancer screening study.

Authors:  Peter J Mazzone; Nancy Obuchowski; Alex Z Fu; Michael Phillips; Moulay Meziane
Journal:  Ann Am Thorac Soc       Date:  2013-08

Review 2.  Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice.

Authors:  Deborah M Miller; Rebecca Allen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

3.  Cost-effectiveness of a behavioral intervention for persistent urinary incontinence in prostate cancer patients.

Authors:  Amy Y Zhang; Alex Z Fu
Journal:  Psychooncology       Date:  2015-05-12       Impact factor: 3.894

4.  Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.

Authors:  Alex Z Fu; Kristi D Graves; Roxanne E Jensen; John L Marshall; Margaret Formoso; Arnold L Potosky
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

5.  A survey of risk tolerance to multiple sclerosis therapies.

Authors:  Robert J Fox; Carol Cosenza; Lauren Cripps; Paul Ford; MaryBeth Mercer; Sneha Natarajan; Amber Salter; Tuula Tyry; Stacey S Cofield
Journal:  Neurology       Date:  2019-03-13       Impact factor: 9.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.